e-learning
resources
London 2016
Tuesday, 06.09.2016
Asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Total and free IgE in evolution of severe asthma after omalizumab treatment
Ebymar Arismendi Nunez (Barcelona, Spain), María del Carmen Vennera, Mariona Pascal, Ebymar Arismendi Nunez, César Picado
Source:
International Congress 2016 – Asthma management
Session:
Asthma management
Session type:
Thematic Poster
Number:
4117
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ebymar Arismendi Nunez (Barcelona, Spain), María del Carmen Vennera, Mariona Pascal, Ebymar Arismendi Nunez, César Picado. Total and free IgE in evolution of severe asthma after omalizumab treatment. Eur Respir J 2016; 48: Suppl. 60, 4117
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma
Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding
Year: 2016
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients
Source: International Congress 2015 – Asthma and lung immunology
Year: 2015
Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
Asthma control, symptoms and exacerbations across treatment levels in patients with asthma
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013
Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
Combined therapy of asthma and allergic rhinitis
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016
APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015
Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy
Source: International Congress 2016 – Clinical and molecular studies in asthma
Year: 2016
Clinical effectiveness of anti-IgE therapy in allergic severe asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013
Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Evaluating omalizumab persistency of response after long-term therapy (XPORT)
Source: International Congress 2014 – Intervening in allergic asthma
Year: 2014
Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
Clinical effectiveness of anti-IgE therapy in severe asthma with fungus sensitization
Source: International Congress 2014 – Non inflammatory monitoring of airway diseases
Year: 2014
FeNO in children with asthma is related to inhaled corticosteroids adherence, not to asthma control
Source: International Congress 2014 – Paediatric asthma: markers and molecules
Year: 2014
A clinically observed variability in serum total IgE in patients being considered for omalizumab therapy
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept